-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KjpSyfpaUaDOWmwaEwxiHVK8krpZkjUynj3Wq7CPPRVztqWUrJ6a2ankHWamAwtj MBZuW8skKFfZp8BphZ2UlQ== 0001104659-06-003152.txt : 20060120 0001104659-06-003152.hdr.sgml : 20060120 20060120172633 ACCESSION NUMBER: 0001104659-06-003152 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060116 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20060120 DATE AS OF CHANGE: 20060120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDICINES CO /DE CENTRAL INDEX KEY: 0001113481 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043324394 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-31191 FILM NUMBER: 06541630 BUSINESS ADDRESS: STREET 1: 8 CAMPUS DRIVE CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-656-1616 FORMER COMPANY: FORMER CONFORMED NAME: MEDICINES CO/ MA DATE OF NAME CHANGE: 20000504 8-K 1 a06-3113_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  January 16, 2006

 

The Medicines Company

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

000-31191

 

04-3324394

(State or Other Jurisdiction
of Incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

8 Campus Drive
Parsippany, New Jersey

 

07054

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (973) 656-1616

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 1.01.  Entry into a Material Definitive Agreement

 

On January 16, 2006, the Compensation Committee of the Board of Directors of The Medicines Company (the “Company”) approved 2005 annual cash bonus payments for the Company’s executive officers in 2005.  The Compensation Committee approved the bonus awards following an assessment of the Company’s achievement of its goals for 2005 and the individual performance of each executive officer during 2005, in accordance with the Company’s annual incentive plan.  The following annual bonus payments were approved:

 

 

 

2005 Annual Bonus Payment

 

 

 

 

 

Clive A. Meanwell
Chief Executive Officer

 

$

200,000

 

 

 

 

 

John P. Kelley
President and Chief Operating Officer

 

$

120,000

 

 

 

 

 

Steven H. Koehler
Senior Vice President and Chief Financial Officer

 

$

100,000

 

 

 

 

 

John D. Richards
Vice President

 

$

60,996

 

 

 

 

 

Paul M. Antinori
Vice President and General Counsel

 

$

80,000

 

 

2


 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

THE MEDICINES COMPANY

 

 

 

 

 

 

Date: January 20, 2006

By:

/s/ Steven H. Koehler

 

 

 

Steven H. Koehler

 

 

Senior Vice President and Chief Financial Officer

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----